Literature DB >> 10229411

The London Fibromyalgia Epidemiology Study: direct health care costs of fibromyalgia syndrome in London, Canada.

K P White1, M Speechley, M Harth, T Ostbye.   

Abstract

OBJECTIVE: To estimate direct health care costs associated with fibromyalgia (FM) within a representative community sample.
METHODS: A random sample of 3395 noninstitutionalized adults was screened for widespread pain. Individuals screening positive were examined for FM. Direct health care costs were compared among those with confirmed FM (FM cases, FC), those with widespread pain not having FM (pain controls, PC), controls without widespread pain (general controls, GC), and a random sample of age, sex and geographically matched controls from the Ontario Health Insurance Plan database (OHIP controls, OC).
RESULTS: One hundred FC (86 women) were compared to 76 PC subjects, 135 GC, and 380 OC. FC used more medications and outpatient health services than PC subjects, and about twice the health services at twice the cost compared to GC and OC. The mean difference in direct costs for health services between FC and OC was $493 Cdn annually (p<0.001).
CONCLUSION: FM has a major effect on direct health care costs.

Entities:  

Mesh:

Year:  1999        PMID: 10229411

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  27 in total

1.  Fibromyalgia: revisiting the literature.

Authors:  Diane Forbes; Andrew Chalmers
Journal:  J Can Chiropr Assoc       Date:  2004-06

2.  Factors associated with temporary work disability in patients with fibromyalgia.

Authors:  J Rivera; J Esteve-Vives; M A Vallejo; J Rejas
Journal:  Rheumatol Int       Date:  2010-05-16       Impact factor: 2.631

Review 3.  Management of fibromyalgia syndrome in 2016.

Authors:  Akiko Okifuji; Jeff Gao; Christina Bokat; Bradford D Hare
Journal:  Pain Manag       Date:  2016-06-16

4.  Healthcare Costs and Medication Adherence Among Patients with Fibromyalgia: Combination Medication vs. Duloxetine, Milnacipran, Venlafaxine, and Pregabalin Initiators.

Authors:  Nicole M Marlow; Kit N Simpson; Ivana A Vaughn; Ara Jo; James S Zoller; Edward B Short
Journal:  Pain Pract       Date:  2017-05-28       Impact factor: 3.183

5.  [Use of resources and costs profile in patients with fibromyalgia or generalized anxiety disorder in primary care settings].

Authors:  Antoni Sicras-Mainar; Milagrosa Blanca-Tamayo; Ruth Navarro-Artieda; Javier Rejas-Gutiérrez
Journal:  Aten Primaria       Date:  2009-02-03       Impact factor: 1.137

6.  Epidemiology, costs, and the economic burden of fibromyalgia.

Authors:  Michael Spaeth
Journal:  Arthritis Res Ther       Date:  2009-06-30       Impact factor: 5.156

7.  Geographic variation of chronic opioid use in fibromyalgia.

Authors:  Jacob T Painter; Leslie J Crofford; Jeffery Talbert
Journal:  Clin Ther       Date:  2013-02-26       Impact factor: 3.393

8.  The impact of Fibromyalgia on health-related quality of life in patients according to age.

Authors:  Ricardo Pereira Campos; Maria Isabel Vázquez
Journal:  Rheumatol Int       Date:  2012-11-15       Impact factor: 2.631

Review 9.  [Fibromyalgia].

Authors:  W Biewer; I Conrad; W Häuser
Journal:  Schmerz       Date:  2004-04       Impact factor: 1.107

10.  Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis.

Authors:  A Boonen; R van den Heuvel; A van Tubergen; M Goossens; J L Severens; D van der Heijde; S van der Linden
Journal:  Ann Rheum Dis       Date:  2004-07-22       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.